These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1172 related articles for article (PubMed ID: 20717121)

  • 21. The use of classic psychedelics among adults: a Danish online survey study.
    Søgaard Juul T; Ebbesen Jensen M; Fink-Jensen A
    Nord J Psychiatry; 2023 May; 77(4):367-378. PubMed ID: 36173202
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychedelics and schizophrenia.
    González-Maeso J; Sealfon SC
    Trends Neurosci; 2009 Apr; 32(4):225-32. PubMed ID: 19269047
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychedelics as Medicines: An Emerging New Paradigm.
    Nichols DE; Johnson MW; Nichols CD
    Clin Pharmacol Ther; 2017 Feb; 101(2):209-219. PubMed ID: 28019026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cessation and reduction in alcohol consumption and misuse after psychedelic use.
    Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW
    J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychedelics and Personality.
    Aixalà M; Dos Santos RG; Hallak JEC; Bouso JC
    ACS Chem Neurosci; 2018 Oct; 9(10):2304-2306. PubMed ID: 29863323
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants.
    Galvão-Coelho NL; Marx W; Gonzalez M; Sinclair J; de Manincor M; Perkins D; Sarris J
    Psychopharmacology (Berl); 2021 Feb; 238(2):341-354. PubMed ID: 33427944
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
    J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psilocybin--summary of knowledge and new perspectives.
    Tylš F; Páleníček T; Horáček J
    Eur Neuropsychopharmacol; 2014 Mar; 24(3):342-56. PubMed ID: 24444771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic drugs, is associated with mystical experiences in a dose-dependent manner.
    Lyvers M; Meester M
    J Psychoactive Drugs; 2012; 44(5):410-7. PubMed ID: 23457892
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology.
    Kelly DF; Heinzerling K; Sharma A; Gowrinathan S; Sergi K; Mallari RJ
    Neurosurgery; 2023 Apr; 92(4):680-694. PubMed ID: 36512813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serotonergic psychedelics LSD & psilocybin increase the fractal dimension of cortical brain activity in spatial and temporal domains.
    Varley TF; Carhart-Harris R; Roseman L; Menon DK; Stamatakis EA
    Neuroimage; 2020 Oct; 220():117049. PubMed ID: 32619708
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Therapeutic Potential of Psilocybin.
    Lowe H; Toyang N; Steele B; Valentine H; Grant J; Ali A; Ngwa W; Gordon L
    Molecules; 2021 May; 26(10):. PubMed ID: 34063505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Psychedelics and mental health: a population study.
    Krebs TS; Johansen PØ
    PLoS One; 2013; 8(8):e63972. PubMed ID: 23976938
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions.
    Garcia-Romeu A; Richards WA
    Int Rev Psychiatry; 2018 Aug; 30(4):291-316. PubMed ID: 30422079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reviewing the Potential of Psychedelics for the Treatment of PTSD.
    Krediet E; Bostoen T; Breeksema J; van Schagen A; Passie T; Vermetten E
    Int J Neuropsychopharmacol; 2020 Jun; 23(6):385-400. PubMed ID: 32170326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treating Addiction: Perspectives from EEG and Imaging Studies on Psychedelics.
    Tófoli LF; de Araujo DB
    Int Rev Neurobiol; 2016; 129():157-85. PubMed ID: 27503452
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.
    Mastinu A; Anyanwu M; Carone M; Abate G; Bonini SA; Peron G; Tirelli E; Pucci M; Ribaudo G; Oselladore E; Premoli M; Gianoncelli A; Uberti DL; Memo M
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674849
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Missing Piece? A Case for Microglia's Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics.
    VanderZwaag J; Halvorson T; Dolhan K; Šimončičová E; Ben-Azu B; Tremblay MÈ
    Neurochem Res; 2023 Apr; 48(4):1129-1166. PubMed ID: 36327017
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice.
    Gobbi G; Inserra A; Greenway KT; Lifshitz M; Kirmayer LJ
    Transcult Psychiatry; 2022 Oct; 59(5):718-724. PubMed ID: 36263521
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.